Literature DB >> 22434337

[Antimicrobial treatment of patients with severe acute exacerbation of COPD].

B Klapdor1, S Ewig.   

Abstract

Chronic obstructive lung disease (COPD) is a leading cause of death worldwide. In patients with acute exacerbations admitted to an intensive care unit (ICU), potentially pathogenic microorganisms can be found in approximately 50%, with Haemophilus influenzae and Streptococcus pneumoniae as the leading strains, followed by enterobacteria and Pseudomonas aeruginosa. Viruses can also be detected in a large proportion of patients. The indication for antimicrobial treatment of acutely exacerbated COPD is still controversial but recommended by guidelines for all patients admitted to an ICU. Appropriate agents for an empiric initial treatment are penicillins + betalactamase inhibitor, 2(nd) and 3(rd) generation cephalosporins, carbapenems, and quinolones. Antimicrobial treatment should be adjusted according to the results of microbial investigation of sputum or endotracheal aspirate.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22434337     DOI: 10.1007/s00063-011-0066-x

Source DB:  PubMed          Journal:  Med Klin Intensivmed Notfmed        ISSN: 2193-6218            Impact factor:   0.840


  30 in total

1.  Standard versus newer antibacterial agents in the treatment of severe acute exacerbation of chronic obstructive pulmonary disease: a randomized trial of trimethoprim-sulfamethoxazole versus ciprofloxacin.

Authors:  Semir Nouira; Soudani Marghli; Lamia Besbes; Riadh Boukef; Monia Daami; Noureddine Nciri; Souheil Elatrous; Fekri Abroug
Journal:  Clin Infect Dis       Date:  2010-07-15       Impact factor: 9.079

2.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

3.  Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease.

Authors:  Sanjay Sethi; Jane Maloney; Lori Grove; Catherine Wrona; Charles S Berenson
Journal:  Am J Respir Crit Care Med       Date:  2006-02-10       Impact factor: 21.405

4.  Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial.

Authors:  S Nouira; S Marghli; M Belghith; L Besbes; S Elatrous; F Abroug
Journal:  Lancet       Date:  2001-12-15       Impact factor: 79.321

5.  Procalcitonin as a prognostic factor in severe acute exacerbation of chronic obstructive pulmonary disease.

Authors:  Blandine Rammaert; Nicolas Verdier; Béatrice Cavestri; Saad Nseir
Journal:  Respirology       Date:  2009-07-30       Impact factor: 6.424

6.  COPD exacerbation: mortality prognosis factors in a respiratory care unit.

Authors:  Myriam Aburto; Cristóbal Esteban; Francisco Javier Moraza; Urko Aguirre; Mikel Egurrola; Alberto Capelastegui
Journal:  Arch Bronconeumol       Date:  2011-02-12       Impact factor: 4.872

7.  Mechanical ventilation of patients on long-term oxygen therapy with acute exacerbations of chronic obstructive pulmonary disease: prognosis and cost-utility analysis.

Authors:  J M Añón; A García de Lorenzo; A Zarazaga; V Gómez-Tello; G Garrido
Journal:  Intensive Care Med       Date:  1999-05       Impact factor: 17.440

8.  Readmission rates and life threatening events in COPD survivors treated with non-invasive ventilation for acute hypercapnic respiratory failure.

Authors:  C M Chu; V L Chan; A W N Lin; I W Y Wong; W S Leung; C K W Lai
Journal:  Thorax       Date:  2004-12       Impact factor: 9.139

9.  Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease.

Authors:  G C Donaldson; T A R Seemungal; A Bhowmik; J A Wedzicha
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

10.  Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease.

Authors:  Johannes M A Daniels; Dominic Snijders; Casper S de Graaff; Fer Vlaspolder; Henk M Jansen; Wim G Boersma
Journal:  Am J Respir Crit Care Med       Date:  2009-10-29       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.